[ANMCO Position paper: Clinical management of hypercholesterolemia in patients with acute coronary syndrome]

G Ital Cardiol (Rome). 2016 Jun;17(6):456-61. doi: 10.1714/2262.24350.
[Article in Italian]

Abstract

LDL-cholesterol (LDL-C) reduction after acute coronary syndromes (ACS) is associated with a significant reduction in ischemic recurrences. Accordingly, international guidelines recommend a reduction of LDL-C below 70 mg/dl in ACS patients. Such a result can be accomplished by using high intensity statins, possibly associated with ezetimibe in selected cases. This document outlines the management strategies that can be consistently implemented in clinical practice in order to achieve and maintain guideline-recommended therapeutic goals.

Publication types

  • Consensus Development Conference
  • English Abstract
  • Guideline
  • Practice Guideline

MeSH terms

  • Acute Coronary Syndrome / blood
  • Acute Coronary Syndrome / drug therapy*
  • Anticholesteremic Agents / therapeutic use
  • Cholesterol, LDL / blood
  • Cholesterol, LDL / drug effects*
  • Drug Therapy, Combination
  • Ezetimibe / therapeutic use
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use*
  • Hypercholesterolemia / blood
  • Hypercholesterolemia / drug therapy*
  • Italy
  • Treatment Outcome

Substances

  • Anticholesteremic Agents
  • Cholesterol, LDL
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Ezetimibe